Carregant...
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, ther...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5737122/ https://ncbi.nlm.nih.gov/pubmed/29296860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008813 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|